Hercules Capital: Why It Deserves A Premium To NAV Valuation (Archive)
Hercules Capital deserves a premium to NAV due to superior returns, low costs, and strong biotech exposure.
This 5-Minute Pitch was originally published on Seeking Alpha. It is shared here to showcase my work and track record. I also publish full 5-Minute Pitches on this site. This will be behind a paywall, accessible to Hunter Tier members.
Elevator Pitch
- Hercules Capital’s 41.6% biotech and healthcare exposure should benefit from improving sector funding, IPO activity, and M&A exits.
- Higher interest rates would increase HTGC’s net investment income and EPS under its disclosed rate-sensitivity assumptions.
- HTGC’s internal management structure supports a low operating cost ratio and consistently superior ROAA and ROAE versus BDC peers.
- Falling post-quarter commitments could constrain portfolio growth if persistent, although management attributes the weakness to temporarily increased deal competition from banks.
- HTGC trades near a trough relative valuation versus BDC peers, while its premium to NAV remains supported by its superior returns profile.
Read the full article here.
